Our mission

About US

Cells for Cells is the largest Chilean biotechnology company, dedicated to the research, development, and commercialization of innovative cell therapies. It also complies with the highest standards of scientific, technological and international quality rigor, through manufacturing processes certified under ISO 9001: 2015. Each therapy is produced in our laboratory with GMP (Good Manufacturing Practices) standards, being the first biotechnology company, in Latin America, with such high quality standards. Our therapies are applied by specialist and duly certified doctors.

At Cells for Cells we are committed to the satisfaction of our customers, being at the forefront of the production of innovative cell therapies for the treatment of degenerative diseases, which comply with national and international regulations of good practices, related to quality and safety. . We focus on continuous improvement thanks to our quality management system based on the ISO 9001: 2015 Standard, we rely on our corporate culture of integrity, respect for the life & dignity of people, excellence and leadership in all our activities and areas of competence.

Leadership and Professionalism

Dr. Fernando Figueroa, MD

Dr. Fernando Figueroa completed his clinical training at the Universities of Montpellier, France, and with a Fogarty fellowship from the National Institutes of Health (NIH) at the University of California Los Angeles (UCLA) and as a visiting researcher at the Rockefeller University in New York... MORE

Maroun Khoury,
PhD

Maroun Khoury, PhD obtained his Doctorate degree in biohealth from the University of Montpellier, France, focusing on gene therapy in joint diseases. A constellation of  gene therapy strategies including RNA interference (siRNA), viral- and liposome-based vectors were used for the treatment of osteoarticular diseases...MORE

Juan Pablo Acevedo,
PhD

Juan Pablo Acevedo studied biology at the Pontificia Universidad Católica de Chile, has a doctorate in Chemical Engineering from the University of Chile and did his post-doctorate at the Max Planck Institute in Germany ... MORE

Maximiliano Kunze, MEng

Maximiliano Kunze Küllmer is a Biomedical Engineer from the Pontifical Catholic University with Minors in Biomaterials and Innovation. He earned his Master's in Biomedical Engineering with a specialization in Tissue and Biomaterial Engineering from Duke University. Max previously worked at the Alliance for Regenerative Medicine (ARM) in Washington DC ... MORE

Matías Vial

Matías Vial has a degree in Business Sciences and a Master in Innovation from the Pontificia Universidad Católica de Chile, with more than 24 years of professional experience in the creation, development, leadership and management of national and international companies. .. MORE

Diego Castro, 
MSc

Diego Castro is a biotechnology engineer from the University of Santiago de Chile, and holds both a Master of Science in Biotechnology and Enterprise from the University of Manchester, ... MORE

Anil Sadarangani,
PhD, MBA

Anil is a biologist from the Pontificia Universidad Católica de Chile, has a master's degree and a doctorate in Biomedical Sciences from the Pontificia Universidad Católica de Chile, and did his postdoctoral work at UC San Diego, USA Subsequently,. .MORE

María Ignacia Cádiz

María Ignacia is a biotechnology engineer from UNAB, Chile and has a postgraduate degree in Innovation and Profitability in Business from the University of Los Andes. María Ignacia joined C4C in 2015, after returning from an internship .. MORE

Jimena Cuenca,
PhD

He studied Biochemistry at the University of Chile, Chile. He then moved to Madrid, Spain, where he did a doctorate in Biochemistry and Molecular Biology, at the Complutense University of Madrid (UCM). She currently works as a Professor and Researcher at the Universidad de los Andes School of Medicine, in addition to holding a position as a researcher at Cells for Cells and Regenero, the Chilean Regenerative Medicine Consortium. MORE

Francisca Alcayaga Miranda,
PhD

Dr. Alcayaga-Miranda obtained her veterinary degree from the Universidad Mayor - Chile. He also obtained a doctorate from the Autonomous University of Barcelona - Spain. From 2006 to 2010, Dr. Alcayaga-Miranda contributed to the development of oncolytic adenoviruses, a class of targeted cancer therapy, as part of her doctoral thesis.